Mj. Glesby et al., USE OF ANTIHERPES DRUGS AND THE RISK OF KAPOSIS-SARCOMA - DATA FROM THE MULTICENTER AIDS COHORT STUDY, The Journal of infectious diseases, 173(6), 1996, pp. 1477-1480
To determine if use of antiherpes drugs protects against the developme
nt of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual
men with AIDS from the Multicenter AIDS Cohort Study were analyzed, In
nested case-control analysis, neither acyclovir use for human immunod
eficiency virus infection (odds ratio [OR], 0.84; 95% confidence inter
val [CI], 0.56-1.26; P = .39) nor acyclovir use for any indication (OR
, 1.02; 95% CI, 0.76-1.38; P = .89) was associated with a reduced risk
of KS as initial AIDS diagnosis, In longitudinal analysis, acyclovir
was also not protective against developing KS as a late manifestation
of AIDS (after initial non-KS AIDS diagnosis), Among men with cytomega
lovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.
22-1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051-3.10; P =
.38) were associated (although not significantly) with a reduced risk
of KS, Thus, acyclovir use does not appear to reduce the risk of KS,
but further study of other antiherpes drugs such as ganciclovir and fo
scarnet is warranted.